Powerful computational tools, such as predictive artificial intelligence (AI) models, are reshaping preclinical research, leading to more optimized and streamlined drug discovery and drug development pipelines.1 In drug discovery, AI can be applied...
Precision oncology (also known as personalized medicine in cancer treatment) is about matching an individual to the optimal therapy for their unique form of cancer. Many people associate personalized medicine with genetic testing. Genomic tumor...
OPTIMIZING BIOMARKER DISCOVERY, MODEL SELECTION AND PRECLINICAL DECISION-MAKING Toronto, ON — April 25, 2023 — In this upcoming live webinar hosted by Xtalks, learn about how artificial intelligence (AI) can bring greater speed and precision to...
Bioinformatics Solution Combines Artificial Intelligence, Maching Learning and Functional Testing to Elevate Precision Cancer Treatment
Presentations to highlight the value of clinically relevant patient-derived xenograft (PDX) models for translational research and drug development
Custom Solutions, Better Translation The ultimate goal of drug development in oncology is to identify drug candidates that will successfully advance through the clinical trial pipeline to FDA approval, thus offering individuals with cancer the hope...
In this educational webinar, learn about the latest innovations in preclinical cancer modeling. This talk will cover advancements in patient-derived xenograft (PDX) development, models of spontaneous metastases and other sophisticated approaches to...
Why do the quaintest analogies stick to biology’s most morbid phenomena? Look no further than English surgeon Stephen Paget’s “seed and soil” model for breast cancer metastasis for a prototypical example. In his 1889 publication in the Lancet, Paget...
San Diego, CA — Certis Oncology Solutions, a life science technology company, announced today the release of its new cancer model database, BarneyOI™. This proprietary, online repository houses deep molecular characterization data for Certis’...
EXECUTIVE SUMMARY Patient-derived xenograft (PDX) models are indispensable for translational cancer research. However, public and private PDX tumor banks may lack standard quality controls, which may lead to genomic and transcriptomic...